Small Molecule Direct Inhibitors of Keap1-Nrf2 Protein-Protein Interaction
Non-covalent direct inhibition of the Keap1-Nrf2 PPI resulting in upregulation of ARE-gene expression. Thus, increase ARE-controlled cytoprotective oxidative stress response enzymes in the development of therapeutic and preventive agents for a number of diseases and conditions.
Invention Summary:
The Keap1-Nrf2-ARE system could protect...
Published: 1/14/2025
|
Inventor(s): Longqin Hu, Ahmed Ali
Keywords(s):
Category(s): Technology Classifications > Therapeutics, Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Cancer
|
New Drugs for the Prevention of Kidney Stones
In vivo efficacy study of an LH prodrug expressed as days CaOx crystals were detected in mouse urine/mouse/week
Invention Summary:
Hyperoxaluria is a condition characterized by excessive urinary excretion of oxalate. It can result from inherited genetic mutations, intestinal diseases, or a diet high in oxalate. This often leads to calcium...
Published: 11/20/2024
|
Inventor(s): Longqin Hu, Yiling Wang
Keywords(s): Drug Discovery/Screening
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|
Novel Inhibitors of Keap1-Nrf2 Protein-Protein Interaction
Novel Small Molecule Direct Inhibitors of Keap1-Nrf2 Protein-Protein Interaction
Invention Summary:
Nrf2 is a key transcription factor mediating anti-inflammatory and antioxidant responses in the body. Keap1 is a well-known repressor of Nrf2 that targets Nrf2 for its rapid proteasomal degradation. Dysfunctional Keap1-Nrf2 axis contributes to...
Published: 12/4/2024
|
Inventor(s): Longqin Hu, Dhulfiqar Abed
Keywords(s): Small molecules
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
|